Search

Stradling

Sonus Pharmaceuticals, Inc. Completes Registered Direct Public Offering

Sonus Pharmaceuticals, Inc.

Registered direct public offering for Sonus Pharmaceuticals, Inc. (Nasdaq: SNUS) – $30.6 million.

Sonus Pharmaceuticals later merged with OncoGenex Technologies to become OncoGenex Pharmaceuticals.